Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination.

Publication date: Jul 13, 2023

Since the emergence of SARS-CoV-2, vaccines targeting COVID-19 have been developed with unprecedented speed and efficiency. CoronaVac, utilising an inactivated form of the COVID-19 virus and the mRNA26 based Pfizer/BNT162b2 vaccines are widely distributed. Beyond the ability of vaccines to induce production of neutralizing antibodies, they might lead to the generation of antibodies attenuating the disease by recruiting cytotoxic and opsonophagocytic functions. However, the Fc-effector functions of vaccine induced antibodies are much less studied than virus neutralization. Here, using systems serology, we follow the longitudinal Fc-effector profiles induced by CoronaVac and BNT162b2 up until five months following the two-dose vaccine regimen. Compared to BNT162b2, CoronaVac responses wane more slowly, albeit the levels remain lower than that of BNT162b2 recipients throughout the entire observation period. However, mRNA vaccine boosting of CoronaVac responses, including response to the Omicron variant, induce significantly higher peak of antibody functional responses with increased humoral breadth. In summary, we show that vaccine platform-induced humoral responses are not limited to virus neutralization but rather utilise antibody dependent effector functions. We demonstrate that this functionality wanes with different kinetics and can be rescued and expanded via boosting with subsequent homologous and heterologous vaccination.

Open Access PDF

Concepts Keywords
Bnt162b2 Antibodies
Covid Antibody
Efficiency Boosting
Inactivated Coronavac
Vaccines Cov


Type Source Name
disease VO vaccination
disease MESH COVID-19
disease VO efficiency
disease VO CoronaVac
disease IDO production
disease VO vaccine
disease VO dose
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH emergency
disease IDO pathogen
drug DRUGBANK Spinosad
disease VO population
disease VO USA
disease MESH Infectious Diseases
disease MESH death
disease VO unvaccinated
disease MESH infection
pathway REACTOME Innate Immune System
disease VO Viruses
drug DRUGBANK Esomeprazole
disease VO vaccine efficacy
disease VO vaccine effectiveness
drug DRUGBANK Coenzyme M
disease MESH joint pain
disease VO inactivated vaccine
disease VO injection
disease VO vaccinated
disease VO time
disease VO immunization
disease VO Optaflu
disease MESH Influenza
disease VO Glycoprotein
disease VO vaccine dose
disease VO titer

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *